Therapeutic Implications of PPARγ in Human Osteosarcoma

Osteosarcoma (OS) is the most common nonhematologic malignancy of bone in children and adults. Although dysregulation of tumor suppressor genes and oncogenes, such as Rb, p53, and the genes critical to cell cycle control, genetic stability, and apoptosis have been identified in OS, consensus genetic changes that lead to OS development are poorly understood. Disruption of the osteogenic differentiation pathway may be at least in part responsible for OS tumorigenesis. Current OS management involves chemotherapy and surgery. Peroxisome proliferator-activated receptor (PPAR) agonists and/or retinoids can inhibit OS proliferation and induce apoptosis and may inhibit OS growth by promoting osteoblastic terminal differentiation. Thus, safe and effective PPAR agonists and/or retinoid derivatives can be then used as adjuvant therapeutic drugs for OS therapy. Furthermore, these agents have the potential to be used as chemopreventive agents for the OS patients who undergo the resection of the primary bone tumors in order to prevent local recurrence and/or distal pulmonary metastasis.

[1]  T. He,et al.  Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cells. , 2009, Differentiation; research in biological diversity.

[2]  T. He,et al.  Retinoic acid signalling induces the differentiation of mouse fetal liver‐derived hepatic progenitor cells , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[3]  B. Carleton,et al.  Thiazolidinediones and fractures in men and women. , 2009, Archives of internal medicine.

[4]  Xia Li,et al.  BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage , 2009, Proceedings of the National Academy of Sciences.

[5]  M. Russo,et al.  Down‐regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells , 2009, Journal of cellular physiology.

[6]  B. Abbott.  Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. , 2009, Reproductive toxicology.

[7]  T. He,et al.  A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. , 2009, Stem cells and development.

[8]  A. Norman,et al.  Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells. , 2009, Molecular endocrinology.

[9]  M. Ladanyi,et al.  The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene , 2009, The Journal of pathology.

[10]  A. Montag,et al.  Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects , 2008, Laboratory Investigation.

[11]  G. Duester.  Retinoic Acid Synthesis and Signaling during Early Organogenesis , 2008, Cell.

[12]  W. Alaynick.  Nuclear receptors, mitochondria and lipid metabolism. , 2008, Mitochondrion.

[13]  C. Kahn,et al.  New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure , 2008, Nature.

[14]  K. Nishida,et al.  Chondrosarcoma and Peroxisome Proliferator-Activated Receptor , 2008, PPAR research.

[15]  T. Guo,et al.  Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells , 2008, Molecular and Cellular Endocrinology.

[16]  T. He,et al.  Osteosarcoma Development and Stem Cell Differentiation , 2008, Clinical orthopaedics and related research.

[17]  P. Dollé,et al.  Retinoic acid in development: towards an integrated view , 2008, Nature Reviews Genetics.

[18]  H. Kuniyasu.  The Roles of Dietary PPARγ Ligands for Metastasis in Colorectal Cancer , 2008, PPAR research.

[19]  F. Khuri,et al.  Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Rajkumar,et al.  Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line , 2008, Anti-cancer drugs.

[21]  M. Jasnis,et al.  Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3 , 2008, BMC Cancer.

[22]  J. Reddy,et al.  Transcription coactivators for peroxisome proliferator-activated receptors. , 2007, Biochimica et biophysica acta.

[23]  J. Auwerx,et al.  PPARγ in human and mouse physiology , 2007 .

[24]  Sang-Oh Yoon,et al.  Pro‐MMP‐2 activation by the PPARγ agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK , 2007, FEBS letters.

[25]  A. Tsantili-Kakoulidou,et al.  Peroxisome proliferator‐activated receptors (PPARs) in the control of bone metabolism , 2007, Fundamental & clinical pharmacology.

[26]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[27]  A. Montag,et al.  Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[28]  A. Bonvin,et al.  Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy. , 2007, Molecular endocrinology.

[29]  T. He,et al.  Osteosarcoma and Osteoblastic Differentiation: A New Perspective on Oncogenesis , 2007, Clinical orthopaedics and related research.

[30]  G. Muscat,et al.  Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor γ Modulator With Antidiabetic Activity , 2006, Diabetes.

[31]  M. Lane,et al.  Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: Role of the BMP-4 gene , 2006, Proceedings of the National Academy of Sciences.

[32]  A. Montag,et al.  CCN1/Cyr61 Is Regulated by the Canonical Wnt Signal and Plays an Important Role in Wnt3A-Induced Osteoblast Differentiation of Mesenchymal Stem Cells , 2006, Molecular and Cellular Biology.

[33]  S. Ishii,et al.  Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins. , 2006, Developmental cell.

[34]  P. Chambon,et al.  Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. , 2006, Annual review of pharmacology and toxicology.

[35]  B. Vernus,et al.  Response of human rhabdomyosarcoma cell lines to retinoic acid: relationship with induction of differentiation and retinoic acid sensitivity. , 2005, Experimental cell research.

[36]  Claudia Eichler-Jonsson,et al.  Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid , 2005, Oncogene.

[37]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[38]  J. Richardson,et al.  Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. , 2005, Cancer research.

[39]  T. He.  Distinct osteogenic activity of BMPs and their orthopaedic applications. , 2005, Journal of musculoskeletal & neuronal interactions.

[40]  Lisa L. Wang.  Biology of osteogenic sarcoma. , 2005, Cancer journal.

[41]  H. Inoue,et al.  Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. , 2005, Biochemical and biophysical research communications.

[42]  A. Parfitt,et al.  Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. , 2005, Endocrinology.

[43]  R. Nemenoff,et al.  Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC) , 2005, Oncogene.

[44]  B. P. Kota,et al.  An overview on biological mechanisms of PPARs. , 2005, Pharmacological research.

[45]  M. Badr,et al.  Aging and enhanced hepatocarcinogenicity by peroxisome proliferator-activated receptor alpha agonists , 2005, Ageing Research Reviews.

[46]  I. Papadaki,et al.  PPARγ expression in breast cancer: clinical value and correlation with ERβ , 2005, Histopathology.

[47]  A. Montag,et al.  Connective Tissue Growth Factor (CTGF) Is Regulated by Wnt and Bone Morphogenetic Proteins Signaling in Osteoblast Differentiation of Mesenchymal Stem Cells* , 2004, Journal of Biological Chemistry.

[48]  David M. Thomas,et al.  Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma , 2004, The Journal of cell biology.

[49]  B. Lecka-Czernik,et al.  Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR‐γ2 transcription factor and TGF‐β/BMP signaling pathways , 2004, Aging cell.

[50]  Jill M Seargent,et al.  GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation , 2004, British journal of pharmacology.

[51]  Philippe Vielh,et al.  Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators , 2004 .

[52]  D. Miao,et al.  Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. , 2004, The Journal of endocrinology.

[53]  M. Lea,et al.  Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. , 2004, Anticancer research.

[54]  Wei Jiang,et al.  Inhibitor of DNA Binding/Differentiation Helix-Loop-Helix Proteins Mediate Bone Morphogenetic Protein-induced Osteoblast Differentiation of Mesenchymal Stem Cells* , 2004, Journal of Biological Chemistry.

[55]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[56]  T. Casavant,et al.  Gene expression profiling of potential PPARγ target genes in mouse aorta , 2004 .

[57]  Kozo Nakamura,et al.  PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. , 2004, The Journal of clinical investigation.

[58]  Hongwei Cheng,et al.  Transcriptional characterization of bone morphogenetic proteins (BMPs)‐mediated osteogenic signaling , 2003, Journal of cellular biochemistry.

[59]  P. Meltzer,et al.  Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  A. Sandberg,et al.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. , 2003, Cancer genetics and cytogenetics.

[61]  K. Park,et al.  Activation of Peroxisome Proliferator-activated Receptor-γ Inhibits the Runx2-mediated Transcription of Osteocalcin in Osteoblasts* , 2003, Journal of Biological Chemistry.

[62]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[63]  I. Hickson.  RecQ helicases: caretakers of the genome , 2003, Nature Reviews Cancer.

[64]  P. Roy-Burman,et al.  Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. , 2002, Cancer research.

[65]  J. Lehmann,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Divergent Effects of Selective Peroxisome Proliferator- Activated Receptor-�2 Ligands on Adipocyte Versus Osteoblast Differentiation , 2022 .

[66]  Jeffrey L. Wrana,et al.  Signal Transduction by the TGF-β Superfamily , 2002, Science.

[67]  A. Montag,et al.  Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  J. Barsony,et al.  Degradation of RXRs influences sensitivity of rat osteosarcoma cells to the antiproliferative effects of calcitriol. , 2002, Molecular endocrinology.

[69]  S. Hilsenbeck,et al.  Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[70]  H. Inoue,et al.  Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ , 2002, British Journal of Cancer.

[71]  P. Picci,et al.  Troglitazione affects survival of human osteosarcoma cells , 2002, International journal of cancer.

[72]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[73]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[74]  B. Spiegelman,et al.  PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.

[75]  M. Wente,et al.  Peroxisome Proliferator-Activated Receptor γ Induces Pancreatic Cancer Cell Apoptosis , 2001 .

[76]  W. Hsueh,et al.  Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. , 2001, Biochemical and biophysical research communications.

[77]  S. Rabbani,et al.  Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. , 2001, American journal of physiology. Endocrinology and metabolism.

[78]  G. Brent,et al.  Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms. , 2001, The Journal of endocrinology.

[79]  F. Kraemer,et al.  Human BMP‐7/OP‐1 induces the growth and differentiation of adipocytes and osteoblasts in bone marrow stromal cell cultures * , 2001, Journal of cellular biochemistry.

[80]  W. C. Forrester,et al.  The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. , 2001, Molecular cell.

[81]  K Ohta,et al.  Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. , 2001, The Journal of clinical endocrinology and metabolism.

[82]  G. Wood,et al.  Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.

[83]  Takuji Tanaka,et al.  Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. , 2001, Cancer research.

[84]  N. Messaddeq,et al.  RXR-alpha ablation in skin keratinocytes results in alopecia and epidermal alterations. , 2001, Development.

[85]  M. Edin,et al.  Selective Drug Resistant Human Osteosarcoma Cell Lines , 2001, Clinical orthopaedics and related research.

[86]  B. Park,et al.  Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer , 2001, Current opinion in oncology.

[87]  AkiraTakeshita,et al.  Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells , 2000 .

[88]  G. Karsenty,et al.  The osteoblast: a sophisticated fibroblast under central surveillance. , 2000, Science.

[89]  J. Horowitz,et al.  Effect of endurance training on lipid metabolism in women: a potential role for PPARalpha in the metabolic response to training. , 2000, American journal of physiology. Endocrinology and metabolism.

[90]  H. Chien,et al.  Down-Regulation of Osteoblastic Cell Differentiation by Epidermal Growth Factor Receptor , 2000, Calcified Tissue International.

[91]  W. Hsueh,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Retinoblastoma Phosphorylation and G1 → S Transition in Vascular Smooth Muscle Cells* , 2000, The Journal of Biological Chemistry.

[92]  C. Sigman,et al.  Retinoids in chemoprevention and differentiation therapy. , 2000, Carcinogenesis.

[93]  K. Seuwen,et al.  Bone morphogenetic protein‐2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone) , 2000, FEBS letters.

[94]  G. Karsenty,et al.  The family of bone morphogenetic proteins. , 2000, Kidney international.

[95]  J. Pitts,et al.  PPARgamma: observations in the hematopoietic system. , 2000, Prostaglandins & other lipid mediators.

[96]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[97]  J. Corton,et al.  Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators. , 2000, Mutation research.

[98]  E. Williamson,et al.  A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. , 2000, Journal of the National Cancer Institute.

[99]  T. Chang,et al.  Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. , 2000, Cancer research.

[100]  M. Aizawa,et al.  Osteogenesis coordinated in C3H10T1/2 cells by adipogenesis-dependent BMP-2 expression system. , 2000, Tissue engineering.

[101]  Guillaume Adelmant,et al.  Activation of PPARγ coactivator-1 through transcription factor docking , 1999 .

[102]  N. Kamada,et al.  Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. , 1999, International journal of oncology.

[103]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[104]  S. Kaste,et al.  Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis , 1999, Cancer.

[105]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[106]  S. Jameson,et al.  Expression of the transcription factor lung Krüppel-like factor is regulated by cytokines and correlates with survival of memory T cells in vitro and in vivo. , 1999, Journal of immunology.

[107]  M. Osborne.  Breast Cancer Prevention by Antiestrogens , 1999, Annals of the New York Academy of Sciences.

[108]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[109]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[110]  R. Jilka,et al.  Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2 , 1999, Journal of cellular biochemistry.

[111]  T. Okumura,et al.  Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells , 1999 .

[112]  G. Rodan,et al.  Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. , 1999, Endocrinology.

[113]  M. Mochizuki,et al.  1,25-Dihydroxyvitamin D3, recombinant human transforming growth factor-beta 1, and recombinant human bone morphogenetic protein-2 induce in vitro differentiation of canine osteosarcoma cells. , 1999, The Journal of veterinary medical science.

[114]  R. Morrison,et al.  Role of PPARγ in Regulating a Cascade Expression of Cyclin-dependent Kinase Inhibitors, p18(INK4c) and p21(Waf1/Cip1), during Adipogenesis* , 1999, The Journal of Biological Chemistry.

[115]  J. Auwerx,et al.  An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer , 1999, Cellular and Molecular Life Sciences CMLS.

[116]  B. Spiegelman,et al.  Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer , 1999 .

[117]  Margaret S. Wu,et al.  Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects* , 1999, The Journal of Biological Chemistry.

[118]  Y. Matsuzawa,et al.  Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer Cells , 1999, Japanese journal of cancer research : Gann.

[119]  S. Takeshita,et al.  Role of epidermal growth factor and its receptor in mechanical stress-induced differentiation of human periodontal ligament cells in vitro. , 1998, Archives of oral biology.

[120]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[121]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[122]  C. Yen,et al.  Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. , 1998, Diabetes.

[123]  P. Picci,et al.  C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression , 1998, Oncology.

[124]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[125]  A. Pfeiffer,et al.  Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. , 1998, The New England journal of medicine.

[126]  J. G. Alvarez,et al.  Activators of the nuclear receptor PPARγ enhance colon polyp formation , 1998, Nature Medicine.

[127]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[128]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[129]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[130]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[131]  C. Glass,et al.  Co-activators and co-repressors in the integration of transcriptional responses. , 1998, Current opinion in cell biology.

[132]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[133]  H. Kimura,et al.  Prognosis of Osteosarcoma With Pulmonary Metastases at Initial Presentation Is Not Dismal , 1998, Clinical orthopaedics and related research.

[134]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[135]  A. Reddi,et al.  Role of morphogenetic proteins in skeletal tissue engineering and regeneration , 1998, Nature Biotechnology.

[136]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[137]  G. Rodan,et al.  High Fatty Acid Content in Rabbit Serum Is Responsible for the Differentiation of Osteoblasts Into Adipocyte‐like Cells , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[138]  B. Spiegelman,et al.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. , 1997, Genes & development.

[139]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[140]  M. Takiguchi,et al.  Identification of an extended half‐site motif required for the function of peroxisome proliferator‐activated receptor α , 1997, Genes to cells : devoted to molecular & cellular mechanisms.

[141]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[142]  W F Bodmer,et al.  Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[143]  B. Spiegelman,et al.  Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[144]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[145]  P. Terrier,et al.  Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  Philippe Kastner,et al.  Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.

[147]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[148]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[149]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[150]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[151]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[152]  Kai Yu,et al.  Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.

[153]  B. Spiegelman,et al.  Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. , 1995, Current opinion in genetics & development.

[154]  J Auwerx,et al.  Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*) , 1995, The Journal of Biological Chemistry.

[155]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[156]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[157]  Y. Tokuumi.  [Correlation between the concentration of 1,25 alpha dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3]. , 1995, Nihon Seikeigeka Gakkai zasshi.

[158]  B M Raaka,et al.  The ligand-binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing, and transactivation , 1995, Molecular and cellular biology.

[159]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[160]  D. Moore,et al.  The peroxisome proliferator activated receptor regulates malic enzyme gene expression. , 1994, The Journal of biological chemistry.

[161]  R. Scott,et al.  Adipocyte differentiation selectively represses the serum inducibility of c-jun and junB by reversible transcription-dependent mechanisms. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[162]  J. Poen,et al.  Postirradiation sarcomas. A single‐institution study and review of the literature , 1994, Cancer.

[163]  J. Reddy,et al.  Association of peroxisome proliferator-activated receptor and Hsp72. , 1994, The Journal of biological chemistry.

[164]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[165]  G. Gross,et al.  Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. , 1993, DNA and cell biology.

[166]  J. German.  Bloom Syndrome: A Mendelian Prototype of Somatic Mutational Disease , 1993, Medicine.

[167]  A. Mahfoudi,et al.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[168]  G. Rodan,et al.  Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. , 1992, Molecular endocrinology.

[169]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[170]  R. Scott,et al.  Insulin‐induced mitogenesis associated with transformation by the SV40 large T antigen , 1991, Journal of cellular physiology.

[171]  J. Shine,et al.  1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. , 1989, Science.

[172]  K. Unni,et al.  Osteosarcoma: pathology and classification. , 1989, Seminars in roentgenology.

[173]  R. Scott,et al.  Nonterminally differentiated cells express decreased growth factor responsiveness , 1989, Journal of cellular physiology.

[174]  H. Kronenberg,et al.  Regions of the rat osteocalcin gene which mediate the effect of 1,25-dihydroxyvitamin D3 on gene transcription. , 1989, The Journal of biological chemistry.

[175]  D M Green,et al.  Bone sarcomas linked to radiotherapy and chemotherapy in children. , 1987, The New England journal of medicine.

[176]  M. Housset,et al.  Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells? , 1982, British journal of haematology.

[177]  Dahlin Dc,et al.  Postradiation sarcoma of bone: review of 78 Mayo Clinic cases , 1981 .

[178]  R. Blamey,et al.  Estrogen receptors and breast cancer. , 1981, Environmental health perspectives.

[179]  W. Bean.  Annual Review of Medicine, Vol. 7 , 1957, Pediatrics.

[180]  高野 正太.  Pioglitazone, a ligand for peroxisome proliferator-activated receptor-γ acts as an inhibitor of colon cancer liver metastasis , 2010 .

[181]  S. Baek,et al.  Molecular characterisation of canine nonsteroidal anti-inflammatory drug-activated gene (NAG-1). , 2008, Veterinary journal.

[182]  S. Muruganandan,et al.  Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: Cross talk with the osteoblastogenic program , 2008, Cellular and Molecular Life Sciences.

[183]  A. Montag,et al.  Regulation of osteogenic differentiation during skeletal development. , 2008, Frontiers in bioscience : a journal and virtual library.

[184]  W. Thilly,et al.  Stem cell stages and the origins of colon cancer , 2007, Stem Cell Reviews.

[185]  C. Xiaoguang.  Antineoplastic effects of peroxisome proliferator activated receptorγ agonists , 2005 .

[186]  J. Aubin.  Regulation of Osteoblast Formation and Function , 2004, Reviews in Endocrine and Metabolic Disorders.

[187]  L. Mosekilde,et al.  Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis , 2004, Biogerontology.

[188]  L. Suva,et al.  Bone is a target for the antidiabetic compound rosiglitazone. , 2004, Endocrinology.

[189]  S. Salzano,et al.  Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Induces the Osteoblastic Differentiation of the Human Osteosarcoma Cell Line SaOS-2 , 2002, Calcified Tissue International.

[190]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[191]  S. Mudaliar,et al.  New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. , 2001, Annual review of medicine.

[192]  Y. Hirasawa,et al.  Oral administration of 1 alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model. , 2001, Anticancer research.

[193]  J. Corton,et al.  Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. , 2000, Annual review of pharmacology and toxicology.

[194]  M. Merino,et al.  A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[195]  R. Scott,et al.  Differentiation, differentiation/gene therapy and cancer. , 1997, Pharmacology & therapeutics.

[196]  R. DuBois,et al.  Colorectal cancer and nonsteroidal anti-inflammatory drugs. , 1997, Advances in pharmacology.

[197]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[198]  E. Wang,et al.  Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. , 1993, Growth factors.

[199]  E. Besa.  Acute promyelocytic leukemia. , 1991, Blood.

[200]  R. Weatherby,et al.  Postradiation sarcoma of bone: review of 78 Mayo Clinic cases. , 1981, Mayo Clinic proceedings.